{"DataElement":{"publicId":"6044858","version":"1","preferredName":"Hypersensitivity Third Or Fourth Generation Cephalosporin Antibiotic Carbapenems Aminoglycoside Antibiotic Eligibility Determination Indicator","preferredDefinition":"The response that indicates the patient meets the eligibility requirements for participation in a clinical trial with regard to hypersensitivity to a third or fourth generation cephalosporin, carbapenem, or aminoglycoside  antibiotic agents.","longName":"HYPRSENS_CRB_CPH_AMG_IND","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"6044805","version":"1","preferredName":"Hypersensitivity Third Or Fourth Generation Cephalosporin Antibiotic Carbapenems Aminoglycoside Antibiotic Eligibility Determination","preferredDefinition":"An immune response that occurs following exposure to an innocuous antigen, but that does not require the presence of preformed antibodies to the antigen._Following the second position in an ordering or series; coming next after the second and just before the fourth in position._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Following the third position in an ordering or series; coming next after the third and just before the fifth in position._A single step in the line of descent from a common ancestor._A drug used to treat bacterial infections. It belongs to the family of drugs called antibiotics._A group of beta-lactam antibiotics in which the sulfur atom in the thiazolidine ring of the penicillin molecule is replaced by a carbon atom. THIENAMYCINS are a subgroup of carbapenems which have a sulfur atom as the first constituent of the side chain._A family of antibiotics that works against many types of bacteria and includes streptomycin, gentamicin, and neomycin. Aminoglycosides are used to treat bacterial infections._Criteria to determine eligibility of patients for medical care programs and services.","longName":"2590026v1.0:6044803v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2590026","version":"1","preferredName":"Hypersensitivity","preferredDefinition":"Hypersensitivity; a local or general reaction of an organism following contact with a specific allergen to which it has been previously exposed and to which it has become sensitized.","longName":"C3114","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypersensitivity","conceptCode":"C3114","definition":"An immune response that occurs following exposure to an innocuous antigen, but that does not require the presence of preformed antibodies to the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"27A683DB-004C-1DAD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-22","endDate":null,"createdBy":"UMLLOADER_CAISIS","dateCreated":"2007-01-22","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6044803","version":"1","preferredName":"Third Or Fourth Generation Cephalosporin Antibiotic Carbapenems Aminoglycoside Antibiotic Eligibility Determination","preferredDefinition":"Following the second position in an ordering or series; coming next after the second and just before the fourth in position.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Following the third position in an ordering or series; coming next after the third and just before the fifth in position.:A single step in the line of descent from a common ancestor.:A drug used to treat bacterial infections. It belongs to the family of drugs called antibiotics.:A group of beta-lactam antibiotics in which the sulfur atom in the thiazolidine ring of the penicillin molecule is replaced by a carbon atom. THIENAMYCINS are a subgroup of carbapenems which have a sulfur atom as the first constituent of the side chain.:A family of antibiotics that works against many types of bacteria and includes streptomycin, gentamicin, and neomycin. Aminoglycosides are used to treat bacterial infections.:Criteria to determine eligibility of patients for medical care programs and services.","longName":"6044803v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Third","conceptCode":"C25260","definition":"Following the second position in an ordering or series; coming next after the second and just before the fourth in position.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Fourth","conceptCode":"C54566","definition":"Following the third position in an ordering or series; coming next after the third and just before the fifth in position.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Generation","conceptCode":"C88214","definition":"A single step in the line of descent from a common ancestor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Cephalosporin Antibiotic","conceptCode":"C357","definition":"A synthetic or semi-synthetic beta-lactam antibiotic derived from Acremonium (Cephalosporium) fungi with bactericidal activity. Cephalosporin antibiotics bind to and inactivate penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Carbapenems","conceptCode":"C0006968","definition":"A group of beta-lactam antibiotics in which the sulfur atom in the thiazolidine ring of the penicillin molecule is replaced by a carbon atom. THIENAMYCINS are a subgroup of carbapenems which have a sulfur atom as the first constituent of the side chain.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"2"},{"longName":"Aminoglycoside Antibiotic","conceptCode":"C2363","definition":"Any antibiotic containing amino-modified sugars originally isolated from various Streptomyces and Micromonospora species. Aminoglycoside antibiotics bind to the 16S RNA of the bacterial 30S ribosomal subunit, inhibiting translation and protein synthesis. Aminoglycoside use is associated with ototoxicity, neurotxicity and nephrotoxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"60CB0977-7A49-55CD-E053-F662850A54EE","latestVersionIndicator":"Yes","beginDate":"2017-12-20","endDate":null,"createdBy":"HAMMA","dateCreated":"2017-12-20","modifiedBy":"ONEDATA","dateModified":"2017-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"60CB0977-7A5A-55CD-E053-F662850A54EE","latestVersionIndicator":"Yes","beginDate":"2017-12-20","endDate":null,"createdBy":"HAMMA","dateCreated":"2017-12-20","modifiedBy":"MAESKEB","dateModified":"2019-10-21","changeDescription":"Curated for study ACCL1633 Eligibility CRF. 12/20/17 AH.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Is patient allergic to the th","type":"Preferred Question Text","description":"Is patient allergic to the third or fourth generation cephalosporins, carbapenems, or aminoglycosides which are used to empirically treat LBP bacteremia?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Is patient allergic to all third or fourth generation cephalosporins, carbapenems, and all aminoglycosides which are used to empirically treat LBP bacteremia?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"60CFB06D-F1F4-13DA-E053-F662850AA458","latestVersionIndicator":"Yes","beginDate":"2017-12-20","endDate":null,"createdBy":"HAMMA","dateCreated":"2017-12-20","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":"Curated for study ACCL1633 Eligibility CRF. 12/20/17 AH.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}